Lawyers from Beasley, Allen, Crow, Methvin, Portis & Miles, P.C., have filed a lawsuit on behalf of the City of Greenville, Alabama, against a number of manufacturers and distributors of prescription opioid medications. The complaint alleges the marketing of these drugs contributed to the creation of the opioid epidemic, a public health and safety crisis, and as a result of responding to the opioid crisis within its communities the City of Greenville has sustained economic damages and continues to incur a significant financial burden. The City of Greenville is represented by Beasley Allen lawyers Rhon E. Jones, who is head of the firm’s Toxic Torts Section, Rick Stratton, Will Sutton and Ryan Kral.
“These manufacturers aggressively pushed highly addictive, dangerous opioids, turning patients into addicts for their own corporate profits,” Jones said. “The manufacture and distribution of these dangerous drugs, along with the intentional misrepresentation to doctors and the public about their risks, breached these companies’ legal duties under federal and state law. Rather than investigate suspicious orders of prescription opiates, they simply pocketed the profits at the expense of the public.”
Economic damages resulting from the opioid epidemic include costs for providing medical care, therapeutic care and treatments for patients suffering from opioid-related addiction or disease, including overdoses and deaths; costs for providing counseling and rehabilitation services; costs for treating infants born with opioid-related medical conditions; public safety and law enforcement expenses; and care for children whose parents suffer from opioid-related disability or incapacitation.
Defendants include Purdue Pharma L.P.; Purdue Pharma, Inc.; The Purdue Frederick Company, Inc.; Teva Pharmaceutical Industries, LTD.; Teva Pharmaceuticals USA, Inc.; Cephalon, Inc.; Johnson & Johnson; Janssen Pharmaceuticals, Inc.; Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc.; Janssen Pharmaceutica Inc. n/k/a Janssen Pharmaceuticals, Inc.; Noramco, Inc.; Endo Health Solutions Inc.; Endo Pharmaceuticals, Inc.; Allergan PLC f/k/a Actavis PLS; Watson Pharmaceuticals, Inc. n/k/a Actavis, Inc.; Watson Laboratories, Inc.; Actavis, LLC; Actavis Pharm a, Inc. f/k/a Watson Pharma, Inc.; Mallinckrodt plc; Mallinckrodt LLC; McKesson Corporation; Cardinal Health, Inc.; and AmerisourceBergen Drug Corporation.
The complaint is filed in the U.S. District Court for the Middle District of Alabama, case number 2:17-CV-836.